pomalidomide has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Brooks, CL; Chauhan, D; Das, DS; Macri, V; Ray, A; Richardson, P; Song, Y | 1 |
| Anderson, G; Anderson, J; Donnenberg, A; Donnenberg, V; Ghobrial, I; Gries, M; Honjo, T; Kurihara, N; Lentzsch, S; Mapara, MY; Roodman, D; Stirling, D | 1 |
2 other study(ies) available for pomalidomide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dendritic Cells; Disease Models, Animal; Drug Synergism; Humans; Mice; Multiple Myeloma; Neoplastic Stem Cells; Osteoblasts; Osteoclasts; Proteasome Inhibitors; Recombinant Fusion Proteins; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
Topics: Angiogenesis Inhibitors; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Humans; Macrophage Colony-Stimulating Factor; Multiple Myeloma; Myeloid Progenitor Cells; NF-kappa B; Osteoclasts; Proto-Oncogene Proteins; Thalidomide; Trans-Activators | 2006 |